NASDAQ
CytomX Therapeutics, Inc. (CTMX) has a free cash flow growth of -8.98% as of Friday, May 29, 2026. This represents a 18.95% decrease compared to its 12-month average of -7.55%. Free cash flow growth tracks the year-over-year percentage change in cash generated after capital expenditures.
No price data available for this timeframe.